News

Categories

February 13, 2025

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

January 30, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

January 8, 2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

December 12, 2024

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

November 21, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

November 21, 2024

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii), for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 5, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

October 31, 2024

Zymeworks Provides Corporate Update and
Reports Third Quarter 2024 Financial Results

October 29, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

October 25, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

October 21, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

October 10, 2024

Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024